# Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers

> **NCT02934464** · PHASE3 · UNKNOWN · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 280 (estimated)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DRUG:** RAMUCIRUMAB
- **DRUG:** Paclitaxel
- **DRUG:** FOLFOX 4
- **DRUG:** mFOLFOX 6
- **DRUG:** XELOX

## Key facts

- **NCT ID:** NCT02934464
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2021-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02934464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02934464, "Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02934464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*